Experts discuss the brain circuits involved in schizophrenia, the current medications, and new agents in phase 3 trials that do not directly block postsynaptic D2 receptors. Phase 2 data on one of these agents, the TAAR1 agonist ulotaront, are summarized.
Vol 86 • 2025 • Number 3
Read the Current Issue
Original Research
Postpartum Distress in Women With and Without ADHD
Academic Highlights
Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Schizophrenia: A Consensus Panel Report
Academic Highlights
Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Bipolar Type I Disorder: A Consensus Panel Report
In Memoriam
In Memoriam: Terence A. Ketter, MD
Narrative Review
Idiopathic Hypersomnia: Recognition and Management in Psychiatric Practice
Original Research
Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report
Related Articles
Insights
Cognitive Impairment, Reward Pathways and Treatment Challenges in Schizophrenia Video
January 14, 2023
Evaluating different domains of negative symptoms separately to better understand their impact on functional outcomes, particularly cognitive symptoms, is important in the treatment of patients with schizophrenia, especially intervening...
Insights
Sequencing Therapy in the Treatment of Schizophrenia Video
January 14, 2023
Balancing and optimizing safety and efficacy when treating patients with schizophrenia can be challenging. New approaches to treatment may impact symptoms more effectively and contribute to better adherence. Sequencing,...
